Biodesix Pulls in $8 Million in New Financing
Molecular diagnostics company Biodesix announced that it has closed $8.4 million in Series E financing. The capital will help develop the company’s mass-spec technology platform and market the company’s first test, VeriStat, to guide NSCLC therapy.
Read More